Antimicrobials
Chloroquine

Chloroquine

Low
Excellent (90 to 100%)

Spectrum of Activity

Dosing

General Information

  • Malaria
  • Extraintestinal amebiasis

Hypersensitivity to Chloroquine or any components of the formulation.

  • ECG: To monitor for any QT interval prolongation
  • Monitor liver and kidney function
  • Monitor CBC with differential
  • Ophthalmologic exam at baseline to screen for retinal toxicity. Consider annual exams in patients with significant risk factors
  • CNS: Agitation, anxiety, decreased tendon reflex, seizure, psychosis
  • CV: QT prolongation, cardiac arrhythmia
  • Dermatologic: Alopecia, Bleaching of hair, blue-gray skin pigmentation
  • Endocrine: Hypoglycemia
  • GI: Abdominal cramps, nausea, vomiting
  • Hematologic & oncologic: Aplastic anemia, hemolytic anemia (in G6PD-deficient patients), neutropenia, pancytopenia, thrombocytopenia
  • Hepatic: Hepatitis
  • Ophthalmic: Blurred vision, corneal opacity, Macular degeneration, retinopathy, visual field defect
  • Otic: Hearing loss (risk increased in patients with preexisting auditory damage), tinnitus
  • May enhance hypoglycemic effects of anti-diabetic agents.
  • Antacids may decrease bioavailability of hydroxychloroquine.
  • Dapsone may increase adverse events of hydroxychlotoquine.
  • Avoid concurrent use with any QT-prolonging agent.
  • Chloroquine may diminish the  efficacy of remdesivir. Avoid combination.

Antimicrobial class: Antimalarial

Absorption: Rapid and almost complete

Distribution: Widely in body tissue

Pregnancy: No category assigned by FDA. Use only if benefits outweigh risks

Lactations: Compatible